IL164564A0 - Combination therapy for the treatment of cancer - Google Patents
Combination therapy for the treatment of cancerInfo
- Publication number
- IL164564A0 IL164564A0 IL16456404A IL16456404A IL164564A0 IL 164564 A0 IL164564 A0 IL 164564A0 IL 16456404 A IL16456404 A IL 16456404A IL 16456404 A IL16456404 A IL 16456404A IL 164564 A0 IL164564 A0 IL 164564A0
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- effective amount
- combination therapy
- warm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0208680A GB0208680D0 (en) | 2002-04-16 | 2002-04-16 | Combination therapy |
GB0218388A GB0218388D0 (en) | 2002-08-08 | 2002-08-08 | Combination therapy |
PCT/GB2003/001617 WO2003088971A1 (en) | 2002-04-16 | 2003-04-14 | Combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL164564A0 true IL164564A0 (en) | 2005-12-18 |
Family
ID=29252451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16456404A IL164564A0 (en) | 2002-04-16 | 2004-10-13 | Combination therapy for the treatment of cancer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050215530A1 (id) |
EP (1) | EP1496909B1 (id) |
JP (1) | JP2005530735A (id) |
KR (1) | KR20040103964A (id) |
CN (1) | CN100352441C (id) |
AT (1) | ATE353650T1 (id) |
AU (1) | AU2003216558B2 (id) |
BR (1) | BR0309226A (id) |
CA (1) | CA2482591A1 (id) |
DE (1) | DE60311788T2 (id) |
ES (1) | ES2280735T3 (id) |
HK (1) | HK1071310A1 (id) |
IL (1) | IL164564A0 (id) |
MX (1) | MXPA04010166A (id) |
NO (1) | NO20044498L (id) |
NZ (1) | NZ535739A (id) |
WO (1) | WO2003088971A1 (id) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
AU2004248968A1 (en) * | 2003-06-18 | 2004-12-29 | Angiogene Pharmaceuticals Limited | Compositions comprising ZD6126 together with 5-FU, CPT-11 or 5-FU and CPT-11 having vascular damaging activity for treating e.g. colorectal cancer |
UA83509C2 (en) * | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
CN102924458B (zh) * | 2004-04-02 | 2014-11-05 | Osi制药有限责任公司 | 6,6-双环取代的杂双环蛋白激酶抑制剂 |
AU2005251722B2 (en) * | 2004-06-03 | 2009-11-12 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
NZ551431A (en) | 2004-06-03 | 2010-04-30 | Hoffmann La Roche | Treatment with cisplatin and an EGFR-inhibitor |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
FR2886151B1 (fr) * | 2005-05-31 | 2007-09-07 | Mayoly Spindler Soc Par Action | Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP2250173A1 (en) * | 2008-01-18 | 2010-11-17 | OSI Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
WO2010107968A1 (en) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
WO2010129740A1 (en) * | 2009-05-07 | 2010-11-11 | Osi Pharmaceuticals, Inc. | Use of osi-906 for treating adrenocortical carcinoma |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
-
2003
- 2003-04-14 CA CA002482591A patent/CA2482591A1/en not_active Abandoned
- 2003-04-14 CN CNB03813702XA patent/CN100352441C/zh not_active Expired - Fee Related
- 2003-04-14 BR BR0309226-7A patent/BR0309226A/pt not_active IP Right Cessation
- 2003-04-14 WO PCT/GB2003/001617 patent/WO2003088971A1/en active IP Right Grant
- 2003-04-14 AU AU2003216558A patent/AU2003216558B2/en not_active Ceased
- 2003-04-14 AT AT03712464T patent/ATE353650T1/de not_active IP Right Cessation
- 2003-04-14 NZ NZ535739A patent/NZ535739A/en unknown
- 2003-04-14 KR KR10-2004-7016666A patent/KR20040103964A/ko not_active Application Discontinuation
- 2003-04-14 DE DE60311788T patent/DE60311788T2/de not_active Expired - Fee Related
- 2003-04-14 EP EP03712464A patent/EP1496909B1/en not_active Expired - Lifetime
- 2003-04-14 ES ES03712464T patent/ES2280735T3/es not_active Expired - Lifetime
- 2003-04-14 JP JP2003585723A patent/JP2005530735A/ja active Pending
- 2003-04-14 MX MXPA04010166A patent/MXPA04010166A/es active IP Right Grant
- 2003-04-14 US US10/511,744 patent/US20050215530A1/en not_active Abandoned
-
2004
- 2004-10-13 IL IL16456404A patent/IL164564A0/xx unknown
- 2004-10-21 NO NO20044498A patent/NO20044498L/no not_active Application Discontinuation
-
2005
- 2005-05-23 HK HK05104297A patent/HK1071310A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE353650T1 (de) | 2007-03-15 |
EP1496909A1 (en) | 2005-01-19 |
EP1496909B1 (en) | 2007-02-14 |
AU2003216558B2 (en) | 2008-05-29 |
AU2003216558A1 (en) | 2003-11-03 |
CN100352441C (zh) | 2007-12-05 |
HK1071310A1 (en) | 2005-07-15 |
NO20044498L (no) | 2004-11-04 |
NZ535739A (en) | 2008-01-31 |
MXPA04010166A (es) | 2005-02-03 |
BR0309226A (pt) | 2005-02-09 |
WO2003088971A1 (en) | 2003-10-30 |
KR20040103964A (ko) | 2004-12-09 |
ES2280735T3 (es) | 2007-09-16 |
JP2005530735A (ja) | 2005-10-13 |
DE60311788T2 (de) | 2007-11-22 |
US20050215530A1 (en) | 2005-09-29 |
CA2482591A1 (en) | 2003-10-30 |
DE60311788D1 (de) | 2007-03-29 |
CN1658880A (zh) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
ZA200600188B (en) | Combination therapy | |
NO20064753L (no) | Kombinasjonsterapi | |
WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine | |
BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
GB0223379D0 (en) | Combination therapy |